Finally, both ddPCR and the sequencing of longitudinal samples validated the CAVE results, showing not only that low-VAF TP53 variants identified by CAVE are observed in tumors, but also that their burden increases over the years during tumor progression. Here, TP53 is linked to neoplasm.